PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Tarsus Pharmaceuticals, Inc. (TARS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US87650L1035

CUSIP

87650L103

Sector

Healthcare

IPO Date

Oct 16, 2020

Highlights

Market Cap

$2.11B

EPS (TTM)

-$3.75

Total Revenue (TTM)

$116.55M

Gross Profit (TTM)

$108.65M

EBITDA (TTM)

-$86.10M

Year Range

$20.08 - $57.14

Target Price

$66.00

Short %

20.45%

Short Ratio

12.17

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
TARS vs. APO TARS vs. AAPL
Popular comparisons:
TARS vs. APO TARS vs. AAPL

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Tarsus Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%80.00%100.00%AugustSeptemberOctoberNovemberDecember2025
65.15%
2.98%
TARS (Tarsus Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Tarsus Pharmaceuticals, Inc. had a return of -15.08% year-to-date (YTD) and 112.76% in the last 12 months.


TARS

YTD

-15.08%

1M

-10.44%

6M

67.93%

1Y

112.76%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.66%

1M

-3.44%

6M

3.10%

1Y

22.14%

5Y*

12.04%

10Y*

11.24%

*Annualized

Monthly Returns

The table below presents the monthly returns of TARS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202434.52%40.31%-4.89%-13.54%4.87%-17.54%-10.63%11.61%21.32%35.27%17.89%5.57%173.43%
20237.50%-1.71%-18.85%18.70%12.27%7.88%21.80%-20.45%1.48%-19.86%16.08%22.50%38.13%
2022-10.80%-12.16%-4.59%8.86%-24.90%6.18%2.88%2.40%11.31%7.59%-8.74%-12.79%-34.84%
2021-8.78%-3.85%-11.09%-4.69%8.46%-13.03%-22.12%17.41%-18.68%28.82%-4.18%-15.41%-45.56%
2020-0.68%18.25%71.00%100.83%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 91, TARS is among the top 9% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of TARS is 9191
Overall Rank
The Sharpe Ratio Rank of TARS is 9494
Sharpe Ratio Rank
The Sortino Ratio Rank of TARS is 9191
Sortino Ratio Rank
The Omega Ratio Rank of TARS is 8888
Omega Ratio Rank
The Calmar Ratio Rank of TARS is 9292
Calmar Ratio Rank
The Martin Ratio Rank of TARS is 8888
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Tarsus Pharmaceuticals, Inc. (TARS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for TARS, currently valued at 2.04, compared to the broader market-2.000.002.002.041.74
The chart of Sortino ratio for TARS, currently valued at 2.74, compared to the broader market-4.00-2.000.002.004.002.742.35
The chart of Omega ratio for TARS, currently valued at 1.33, compared to the broader market0.501.001.502.001.331.32
The chart of Calmar ratio for TARS, currently valued at 2.17, compared to the broader market0.002.004.006.002.172.62
The chart of Martin ratio for TARS, currently valued at 6.84, compared to the broader market0.0010.0020.006.8410.82
TARS
^GSPC

The current Tarsus Pharmaceuticals, Inc. Sharpe ratio is 2.04. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Tarsus Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00AugustSeptemberOctoberNovemberDecember2025
2.04
1.73
TARS (Tarsus Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Tarsus Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-16.33%
-4.17%
TARS (Tarsus Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Tarsus Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Tarsus Pharmaceuticals, Inc. was 77.67%, occurring on May 6, 2022. Recovery took 643 trading sessions.

The current Tarsus Pharmaceuticals, Inc. drawdown is 16.33%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-77.67%Dec 21, 2020347May 6, 2022643Nov 26, 2024990
-26.19%Nov 6, 202014Nov 25, 20207Dec 7, 202021
-21.76%Oct 22, 20206Oct 29, 20204Nov 4, 202010
-16.33%Jan 7, 20254Jan 13, 2025
-13.32%Dec 15, 20201Dec 15, 20201Dec 16, 20202

Volatility

Volatility Chart

The current Tarsus Pharmaceuticals, Inc. volatility is 14.63%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
14.63%
4.67%
TARS (Tarsus Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Tarsus Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Tarsus Pharmaceuticals, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab